Aligos therapeutics begins dosing in chronic hepatitis b patients in its phase 1 antisense oligonucleotide study (alg-020572-401)

Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete

ALGS Ratings Summary

Quant